Skip to content

Comparison of the Effectiveness of 10% Oxybutynin Topical Gel and 20% Aluminum Chloride in Patients with Primary Hyperhidrosis: a Randomized Double-Blind Controlled Trial

Comparison of the Effectiveness of 10% Oxybutynin Topical Gel and 20% Aluminum Chloride in Patients with Primary Hyperhidrosis: a Randomized Double-Blind Controlled Trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
IRCT
Registry ID
IRCT20221110056463N2
Enrollment
30
Registered
2023-06-13
Start date
2022-11-21
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Hyperhidrosis. Generalized hyperhidrosis

Interventions

Intervention 1: Intervention Group: The First Group: A Patient with Hyperhidrosis of the Palm or Axilla, Is Treated with a Topical Gel Containing 10% Oxybutynin on One Side of the Body. It is Explaine

Sponsors

Kerman University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Primary Excessive Sweating with a Score of 3 or Higher on the Hyperhidrosis Disease Severity Scale (HDSS), at Least in the last 6 Months No Treatment during 6 Months before Entering the Study with Iontophoresis, Botulinum Toxin Injection no Performance of Sympathectomy

Exclusion criteria

Exclusion criteria: Pregnant and Lactating Women People who have Secondary Excessive Sweating due to an External Factor People with Active Skin Disease such as: Psoriasis, Eczema, Seborrhea and Skin Infection, Glaucoma, Urinary Retention, Myasthenia Gravis, Sjögren's Syndrome or Sicca Syndrome History of Allergy to Aluminum Salts

Design outcomes

Primary

MeasureTime frame
Severity of Hyperhidrosis. Timepoint: At the Beginning, Day 30 and 60. Method of measurement: Hyperhidrosis Disease Severity Scale Questionnaire.;Dermatology Quality of Life. Timepoint: At the Beginning, Day 30 and 60. Method of measurement: DLQI Questionnaire.;Severity of Complications. Timepoint: At the Beginning of the Study and Day 30 and 60. Method of measurement: A self-Made Questionnaire with a Score of 0-2 to Check the Severity of the Complication.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNajmeh Ahramyanpour

Kerman University of Medical Sciences

najmeh.pour@gmail.com0098341328237

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026